SDGR Stock Analysis: Schrodinger | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 1.225m USD | 12M Return: -7.9% | US80810D1037 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.8M
Qual. Beats: 1
Rev. Trend: 87.5%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 6.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Schrödinger, Inc. (SDGR) operates a physics-based computational platform used to discover and design novel molecules for pharmaceutical and materials science applications, serving customers in the United States, Asia-Pacific, Europe, the Middle East, and Africa. The company is organized into two segments: a Software business that licenses its discovery platform to life sciences and materials science clients, and a Drug Discovery business that develops its own pipeline of preclinical and clinical programs both internally and through collaborations, including a research and license agreement with Novartis Pharma AG. Headquartered in New York and incorporated in 1990, Schrödinger has been listed on the NASDAQ since its February 2020 IPO.
Schrödinger sits within the Health Care Technology sub-industry, reflecting that its core revenue driver is a subscription- and license-based software platform rather than traditional drug sales. The platform combines physics-based simulation methods with machine learning to model molecular behavior, allowing researchers to virtually screen and prioritize compounds before they are synthesized in the lab.
- Software segment revenue growth drives subscription expansion
- Novartis collaboration advances development candidates toward milestone payments
- Drug Discovery R&D spending widens operating losses as pipeline expands
| Net Income: -54.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA -23.88 > 1.0 |
| NWC/Revenue: 114.5% < 20% (prev 150.6%; Δ -36.05% < -1%) |
| CFO/TA -0.20 > 3% & CFO -126.9m > Net Income -54.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (75.8m) vs 12m ago 3.19% < -2% |
| Gross Margin: 56.87% > 18% (prev 58.48%; Δ -1.61% > 0.5%) |
| Asset Turnover: 38.99% > 50% (prev 34.57%; Δ 4.42% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.46 (Total Current Assets 470.5m - Total Current Liabilities 173.8m) / Total Assets 640.4m |
| B: -1.07 (Retained Earnings -682.9m / Total Assets 640.4m) |
| C: -0.23 (EBIT TTM -153.4m / Avg Total Assets 664.3m) |
| D: 1.06 (Book Value of Equity 329.0m / Total Liabilities 311.4m) |
| Altman-Z'' = -0.88 = CCC |
| DSRI: 1.03 (Receivables 41.1m/36.8m, Revenue 259.0m/237.9m) |
| GMI: 1.03 (GM 58.48% / 56.87%) |
| AQI: 1.18 (AQ_t 0.08 / AQ_t-1 0.07) |
| SGI: 1.09 (Revenue 259.0m / 237.9m) |
| TATA: 0.11 (NI -54.3m - CFO -126.9m) / TA 640.4m) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of August 07, 2026, the stock is trading at USD 17.81 with a total of 2,739,127 shares traded. Over the past week, the price has changed by +16.03%, over one month by +4.76%, over three months by +37.21% and over the past year by -7.91%.
Current recommended Stop Loss: 16.70 (which is 6.2% or 1.5 ATR below the current price).
Schrodinger has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SDGR.
- StrongBuy: 6
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.6 | 15.5% |
P/S = 4.8074
P/B = 3.608
Revenue TTM = 259.0m USD
EBIT TTM = -153.4m USD
EBITDA TTM = -147.4m USD
Long Term Debt = 91.5m USD (estimated: total debt 108.0m - short term 16.5m)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 108.0m USD (from shortLongTermDebtTotal, last quarter) (leases 107.0m already included)
Net Debt = -305.8m USD (calculated: Debt 108.0m - CCE 413.7m)
Enterprise Value = 919.7m USD (1.23b + Debt 108.0m - CCE 413.7m)
Interest Coverage Ratio = unknown (Ebit TTM -153.4m / Interest Expense TTM 0.0)
EV/FCF = -7.06x (Enterprise Value 919.7m / FCF TTM -130.3m)
FCF Yield = -14.17% (FCF TTM -130.3m / Enterprise Value 919.7m)
FCF Margin = -50.29% (FCF TTM -130.3m / Revenue TTM 259.0m)
Net Margin = -20.98% (Net Income TTM -54.3m / Revenue TTM 259.0m)
Gross Margin = 56.87% ((Revenue TTM 259.0m - Cost of Revenue TTM 111.7m) / Revenue TTM)
Gross Margin QoQ = 55.07% (prev 50.43%)
Tobins Q-Ratio = 1.44 (Enterprise Value 919.7m / Total Assets 640.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 108.0m)
Taxrate = 18.67% (1.37m / 7.35m)
NOPAT = -124.8m (EBIT -153.4m * (1 - 18.67%)) [loss with tax shield]
Current Ratio = 2.71 (Total Current Assets 470.5m / Total Current Liabilities 173.8m)
Debt / Equity = 0.33 (Debt 108.0m / totalStockholderEquity, last quarter 329.0m)
Debt / EBITDA = 2.07 (negative EBITDA) (Net Debt -305.8m / EBITDA -147.4m)
Debt / FCF = 2.35 (negative FCF - burning cash) (Net Debt -305.8m / FCF TTM -130.3m)
Total Stockholder Equity = 332.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.18% (Net Income -54.3m / Total Assets 640.4m)
RoE = -16.37% (Net Income TTM -54.3m / Total Stockholder Equity 332.0m)
RoCE = -36.23% (EBIT -153.4m / Capital Employed (Equity 332.0m + L.T.Debt 91.5m))
RoIC = -26.55% (negative operating profit) (NOPAT -124.8m / Invested Capital 470.1m)
WACC = 9.52% (E(1.23b)/V(1.33b) * Re(10.36%) + D(108.0m)/V(1.33b) * Rd(0.0%) * (1-Tc(0.19)))
Discount Rate = 10.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.95 | Cagr: 2.11%
[DCF] Fair Price = unknown (Cash Flow -130.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 87.51 | Revenue CAGR: 12.54% | SUE: 2.48 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.64 | Chg30d=-4.92% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-2.25 | Chg30d=-1.12% | Revisions=-25% | GrowthEPS=-11.3% | GrowthRev=-8.3%
EPS next Year (2027-12-31): EPS=-1.66 | Chg30d=-6.07% | Revisions=-25% | GrowthEPS=+26.2% | GrowthRev=+13.0%